Engineered FGF19ΔKLB protects against intrahepatic cholestatic liver injury in ANIT-induced and Mdr2-/- mice model

doi:10.1186/s12896-023-00810-9

科研成果详情

题名	Engineered FGF19ΔKLB protects against intrahepatic cholestatic liver injury in ANIT-induced and Mdr2-/- mice model
作者	Shi, Lu1; Zhao, Tiantian 1; Huang, Lei 1; Pan, Xiaomin 1; Wu, Tianzhen1; Feng, Xin1; Chen, Taoli1; Wu, Jiamin1; Niu, Jianlou2
发表日期	2023-10-03
发表期刊	BMC BIOTECHNOLOGY 影响因子和分区
语种	英语
原始文献类型	Article ; Journal article (JA)
关键词	FGF19 Hepatocellular carcinoma Bile acids Intrahepatic cholestasis Inflammation Diseases Pathology Bile acid Clinical application Intrahepatic cholestasi Liver injuries Mice models Safety concerns Wild types
其他关键词	GROWTH-FACTOR 19 ; BILE-ACIDS ; FXR ; METABOLISM ; ACTIVATION ; DISEASE
摘要	Background The major safety concern of the clinical application of wild type FGF19 (FGF19(WT)) emerges given that its extended treatment causes hepatocellular carcinoma. Therefore, we previously generated a safer FGF19 variant FGF19(Delta KLB), which have same effects on glycemic control and bile acid production but much less mitogenic activity. However, it remains unclear as to whether FGF19(Delta KLB) ameliorates intrahepatic cholestasis. Results We found that, similar to that of FGF19(WT), the chronic administration of FGF19(Delta KLB) protects mice from cholestatic liver injury in these two models. The therapeutic benefits of FGF19(Delta KLB) on cholestatic liver damage are attributable, according to the following mechanistic investigation, to the reduction of BA production, liver inflammation, and fibrosis. More importantly, FGF19(Delta KLB) did not induce any tumorigenesis effects during its prolonged treatment. Conclusions Together, our findings raise hope that FGF19(Delta KLB) may represent a useful therapeutic strategy for the treatment of intrahepatic cholestasis.
资助项目	Not Applicable.
出版者	BMC
ISSN	1472-6750
EISSN	1472-6750
卷号	23 期号:1
DOI	10.1186/s12896-023-00810-9
页数	14
WOS类目	Biotechnology & Applied Microbiology
WOS研究方向	Biotechnology & Applied Microbiology
WOS记录号	WOS:001076892600001
收录类别	SCIE ; PUBMED ; SCOPUS ; EI
EI入藏号	20234114874773
EI主题词	Mammals
EI分类号	461.6 Medicine and Pharmacology
URL	查看原文
PubMed ID	37789318
SCOPUSEID	2-s2.0-85173622142
通讯作者地址	[Wu, Jiamin]School of Pharmaceutical Science,Wenzhou Medical University,Zhejiang,Wenzhou,325035,China ; [Niu, Jianlou]Pingyang Affiliated Hospital of Wenzhou Medical University,Zhejiang,Wenzhou,325499,China
Scopus学科分类	Biotechnology
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/183203
专题	药学院（分析测试中心）其他_附属平阳医院（平阳县人民医院）
通讯作者	Wu, Jiamin; Niu, Jianlou
作者单位	1.School of Pharmaceutical Science,Wenzhou Medical University,Zhejiang,Wenzhou,325035,China; 2.Pingyang Affiliated Hospital of Wenzhou Medical University,Zhejiang,Wenzhou,325499,China
第一作者单位	温州医科大学
通讯作者单位	温州医科大学; 附属平阳医院（平阳县人民医院）
第一作者的第一单位	温州医科大学
推荐引用方式 GB/T 7714	Shi, Lu,Zhao, Tiantian,Huang, Lei,et al. Engineered FGF19ΔKLB protects against intrahepatic cholestatic liver injury in ANIT-induced and Mdr2-/- mice model[J]. BMC BIOTECHNOLOGY,2023,23(1).
APA	Shi, Lu., Zhao, Tiantian., Huang, Lei., Pan, Xiaomin., Wu, Tianzhen., ... & Niu, Jianlou. (2023). Engineered FGF19ΔKLB protects against intrahepatic cholestatic liver injury in ANIT-induced and Mdr2-/- mice model. BMC BIOTECHNOLOGY, 23(1).
MLA	Shi, Lu,et al."Engineered FGF19ΔKLB protects against intrahepatic cholestatic liver injury in ANIT-induced and Mdr2-/- mice model".BMC BIOTECHNOLOGY 23.1(2023).